About 3-hydroxy-3-methylglutaryl-CoA lyase, cytoplasmic
3-hydroxy-3-methylglutaryl-CoA lyase, cytoplasmic (HMGCLL1) is a protein
from Homo sapiens identified by UniProt accession
Q8TB92, 370 residues long.
MolForge cross-references it against 0 known binders and
28 disease associations.
Target properties
| Protein name | 3-hydroxy-3-methylglutaryl-CoA lyase, cytoplasmic |
| UniProt accession | Q8TB92 |
| Gene | HMGCLL1 |
| Organism | Homo sapiens |
| Length | 370 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (28)
Diseases linked to this target (Open Targets).
- heel bone mineral density · score 0.46
- mean corpuscular volume · score 0.43
- mean corpuscular hemoglobin concentration · score 0.41
- mean corpuscular hemoglobin · score 0.40
- blood protein measurement · score 0.40
- neurofibrillary tangles measurement · score 0.34
- glomerular filtration rate · score 0.33
- venous thromboembolism · score 0.32
- bone quantitative ultrasound measurement · score 0.26
- bone density · score 0.24
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q8TB92-F1 | alphafold | PREDICTED | 84.66 | — |
Amino-acid sequence (370 residues)
MGNVPSAVKH CLSYQQLLRE HLWIGDSVAG ALDPAQTSLL TNLHCFQPDV SGFSVSLAGT VACIHWETSQ LSGLPEFVKI VEVGPRDGLQ NEKVIVPTDI KIEFINRLSQ TGLSVIEVTS FVSSRWVPQM ADHTEVMKGI HQYPGVRYPV LTPNLQGFHH AVAAGATEIS VFGAASESFS KKNINCSIEE SMGKFEEVVK SARHMNIPAR GYVSCALGCP YEGSITPQKV TEVSKRLYGM GCYEISLGDT IGVGTPGSMK RMLESVMKEI PPGALAVHCH DTYGQALANI LTALQMGINV VDSAVSGLGG CPYAKGASGN VATEDLIYML NGLGLNTGVN LYKVMEAGDF ICKAVNKTTN SKVAQASFNA
Explore 3-hydroxy-3-methylglutaryl-CoA lyase, cytoplasmic with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets